Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection in Patients With "Unpredictable" Poor Response to Gonadotropin-Releasing Hormone Antagonist Protocol

被引:0
|
作者
Zhang, Chunhui [1 ]
Wu, Fangrong [1 ]
Wu, Zexuan [1 ]
Sun, Bolan [1 ]
Chen, Cheng [1 ]
Qian, Weiping [1 ]
机构
[1] Peking Univ, Reprod Med Ctr, Shenzhen Hosp, Shenzhen, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷
关键词
ovarian stimulation; unpredictable POR; in vitro fertilization; low-dose hCG; GnRH antagonist; CONTROLLED OVARIAN STIMULATION; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING-HORMONE; RECOMBINANT FSH; WOMEN; SUPPLEMENTATION; FERTILIZATION; GROWTH; CYCLE;
D O I
10.3389/fendo.2021.739773
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose To compare the effects of early and mid-late follicular phase administration of 150 IU of human chorionic gonadotropin (hCG) on gonadotropin-releasing hormone (GnRH) antagonist protocol in "unpredictable" poor ovarian response (POR) women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment. Methods A retrospective single-center cohort study was conducted on 67 patients with "unpredictable" POR in their first IVF/ICSI cycle receiving GnRH antagonist protocol. Patients were treated with a second IVF/ICSI cycle using the same GnRH antagonist protocol with the same starting dose of recombinant follicle-stimulating hormone (rFSH) as the first cycle; a daily dose of 150 IU of hCG was administrated on either stimulation day 1 (Group A, n = 35) or day 6 (Group B, n = 32). The number of oocytes retrieved, number of usable embryos, serum level of estradiol (E-2) on day of hCG trigger, and clinical pregnant outcomes were studied. Results The addition of 150 IU of hCG on either the first day or sixth day of stimulation increases the serum level of E-2, luteinizing hormone (LH), and hCG on the day of hCG trigger. Only the use of 150 IU of hCG on the first stimulation day improved the number of oocytes retrieved, mature of oocytes, and usable embryos, but not the addition of hCG on stimulation day 6. Implantation rate, clinical pregnancy rate, and ongoing pregnancy rate showed an increasing trend in patients receiving 150 IU of hCG in the early phase compared with mid-late phase, even thought there was no statistically significant difference. Conclusions Our study demonstrated that adding 150 IU of hCG in subsequent GnRH antagonist cycle in "unpredictable" poor responders is associated with the improvement of response to stimulation. Furthermore, early follicular phase addition of 150 IU of hCG significantly increased the number of oocytes retrieved and usable embryos than did the mid-late addition of the same dose.
引用
收藏
页数:7
相关论文
共 32 条
  • [1] Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration
    Propst, Anthony M.
    Hill, Micah J.
    Bates, Gordon Wright
    Palumbo, Michelle
    Van Horne, Anne K.
    Retzloff, Matthew G.
    FERTILITY AND STERILITY, 2011, 96 (04) : 898 - 904
  • [2] Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes
    Weitzman, Vanessa N.
    Engmann, Lawrence
    DiLuigi, Andrea
    Maier, Donald
    Nulsen, John
    Benadiva, Claudio
    FERTILITY AND STERILITY, 2009, 92 (01) : 226 - 230
  • [3] Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle
    Kahraman, Korhan
    Berker, Bulent
    Atabekoglu, Cem Somer
    Sonmezer, Murat
    Cetinkaya, Esra
    Aytac, Rusen
    Satiroglu, Hakan
    FERTILITY AND STERILITY, 2009, 91 (06) : 2437 - 2444
  • [4] Association between luteinizing hormone level decrease on the triggering day and pregnancy outcome for in vitro fertilization/intracytoplasmic sperm injection patients following gonadotropin-releasing hormone antagonist protocol: a retrospective cohort study
    Li, Qing-Fang
    Tang, Min-Yue
    Wang, Gui-Quan
    Chen, Xi-Jing
    Feng, Guo-Fang
    Zhu, Yi-Min
    REPRODUCTIVE AND DEVELOPMENTAL MEDICINE, 2024, 8 (01) : 8 - 17
  • [5] Combined Administration of Gonadotropin-releasing Hormone Agonist with Human Chorionic Gonadotropin for Finall Oocyte Maturation in GnRH Antagonist Cycles for in Vitro Fertilization
    Kim, Chung-Hoon
    Ahn, Jun-Woo
    You, Rae-Mi
    Kim, Sung-Hoon
    Chae, Hee-Dong
    Kang, Byung-Moon
    JOURNAL OF REPRODUCTIVE MEDICINE, 2014, 59 (1-2) : 63 - 68
  • [6] Association between luteinizing hormone level decrease on the triggering day and pregnancy outcome for in vitro fertilization/intracytoplasmic sperm injection patients following gonadotropin-releasing hormone antagonist protocol: a retrospective cohor
    Li Qing-Fang
    Tang Min-Yue
    Wang Gui-Quan
    Chen Xi-Jing
    Feng Guo-Fang
    Zhu Yi-Min
    生殖与发育医学(英文), 2024, 08 (01)
  • [7] Effects of increasing serum luteinizing hormone levels during early phase of the gonadotropin-releasing hormone antagonist protocol on clinical outcomes of the in vitro fertilization cycle
    Huang, Qianwen
    Nong, Yingqi
    Zhang, Xiqian
    Huang, Li
    Tang, Ting
    Huang, Ju
    Liu, Fenghua
    GYNECOLOGICAL ENDOCRINOLOGY, 2022, 38 (02) : 135 - 139
  • [8] Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial
    Bassiouny, Yasmin Ahmed
    Dakhly, Dina Mohamed Refaat
    Bayoumi, Yomna Ali
    Hashish, Nawara Mohamed
    FERTILITY AND STERILITY, 2016, 105 (03) : 697 - 702
  • [9] Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles
    Seow, Kok-Min
    Lin, Yu-Hung
    Huang, Lee-Win
    Hsieh, Bih-Chwen
    Huang, Shih-Chia
    Chen, Chin-Yu
    Chen, Pei-Hsin
    Tzeng, Chii-Ruey
    Hwang, Jiann-Loong
    GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (06) : 338 - 342
  • [10] Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study
    Blockeel, Christophe
    Riva, Arianna
    De Vos, Michel
    Haentjens, Patrick
    Devroey, Paul
    FERTILITY AND STERILITY, 2011, 95 (05) : 1714 - U222